hifibio.comCrawled Nov 9, 2026
HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatment
Andreas Raue and Robert Petit discussed HFB301001, a potential cancer treatment with a patient stratification biomarker for solid tumors.
Roshan Kumar and Yun-Yueh Lu presented HFB2009, an anti-Gal-9 neutralizing antibody program for AML and solid tumors.
Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumors
Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterization
Going Global: Insights on the Advantages of Biotech Globalization Published in Drug Discovery Today from HiFiBiO Therapeutics
HiFiBiO SAS announced that Dr. Roshan Kumar will present CelliGO platform results at PEPTalk 2017 in San Diego.
Research in *Nature Scientific Reports* links galectin-9 ablation by malignant cells to reduced tumor growth in a MB49 murine model.
HiFiBiO Therapeutics Announces Oral Presentation at 2023 American Association for Cancer Research (AACR) Annual Meeting
HiFiBiO Therapeutics announced preclinical data for HFB30132A in *Nature Communications*, showing potential for COVID-19 treatment and prevention.
HiFiBiO Therapeutics published findings in *Science* with the Coronavirus Immunotherapy Consortium (CoVIC) on immune modulation research.
HiFiBiO Therapeutics presented its Drug Intelligent Science (DIS) single-cell platform at the AACR Tumor Heterogeneity Virtual Special Conference.
Bradley Bernstein directs the Gene Regulation Observatory at the Broad Institute of MIT and Harvard and co-leads the institute’s Epigenomics Program.
Dave Weitz holds the Mallinckrodt Professorship in Physics & Applied Physics and Systems Biology at Harvard University.
Jérôme Bibette is a professor of soft matter physics at École Supérieure de Chimie Industrielles de Paris (ESPCI) and co-directs the Michelin Advanced Research Initiative there.
Rob Nicol was a Venture Partner at RA Capital Management and previously led the Broad Institute’s Technology Labs.
Fred Dom co-founded HiFiBiO Therapeutics and serves as its Chief Executive Officer, with board roles in Calyxia, Kapsera, and Oncode Accelerator.
HiFiBiO Therapeutics collaborates with partners to advance its IO and I&I portfolio of targeted therapies, including combinations with anti-PD-1.
HiFiBiO Therapeutics develops immunotherapies using its Drug Intelligent Science (DIS) platform for diseases with high unmet needs.
HiFiBiO Therapeutics warns prospective candidates about fraudulent recruitment scams targeting its name.